Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Natrol

This article was originally published in The Tan Sheet

Executive Summary

First quarter 26.2% drop in selling and marketing expenses to $4.7 mil. helps offset 12.8% sales decline to $19.8 mil., Natrol announces May 1. Net income was down 10.7% to $657,000, Chatsworth, Calif.-based supplement marketer says. Revenues impacted by industry-wide slowdown in retail sales and inventory realignment at major accounts. Firm recently introduced a number of products to combat falling revenues (1"The Tan Sheet" April 16, p. 12)

You may also be interested in...



Natrol, Weider New Products Launch To Offset Declining Revenues

Natrol spent roughly $15.4 mil., or 17.6% of net sales in 2000, on retailer incentives such as slotting fees, co-op advertising and rebates in mass outlets, according to the firm's recent 10-K filed with the Securities & Exchange Commission.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel